Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

Porter, John M.; Cutler, Bruce S.; Lee, Bok Y.; Reich, Theobald; Reichle, Frederick A.; Scogin, J T; Strandness, D. Eugene

doi:10.1016/0002-8703(82)90642-1

Cited by 390 publications

(111 citation statements)

References 7 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…These data confirm the earlier double-blind, controlled observations (Accetto, 1982;Porter et al, 1982), made in patients with mild to moderate intermittent claudication. In this study, all the participants at entry were prospective candidates for vascular surgery, but none had progressed to the point of requiring intervention during the trial.…”

Section: Discussionsupporting

confidence: 91%

“…The efficacy of pentoxifylline in treating intermittent claudication has been evaluated under double-blind controlled conditions both in Europe (Accetto, 1982) and in the United States (Porter et al, 1982). Response to treatment in these trials was assessed by measuring the improvement in the initial (ICD) and absolute (ACD) claudication distances elicited on treadmill ergometry under standard conditions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease

Lee

Berkowitz

Savitsky

et al. 1985

Clinical Cardiology

View full text Add to dashboard Cite

Summary:A pilot study of the effects of pentoxifylline in 19 patients with moderate to severe chronic occlusive arterial disease (COAD) is described. The severity of disease was assessed by the degree of limitation in the walking distance on the flat surface ( < 100 m), the absence of peripheral pulses on palpation, the diminished Doppler tibiallbrachial pressure (the ischemic index) at rest, and by contrast arteriography , when available. After a 2-week washout phase, all subjects received pentoxifylline (1200 mg/day) in an open-label manner for a total of 12 weeks. Twelve of the nineteen patients showed a definite increase in exercise tolerance by the end of the study, with a concomitant reduction in ischemic symptoms. All except 3 patients felt they had derived benefit from the medication. In contrast to the clear improvements in walking distance and symptoms, only small effects on noninvasive vascular laboratory measurements were noted. Platelet aggregation, induced by ADP, epinephrine, and collagen, gradually decreased over the study period. Pentoxifylline appears to be useful in the medical management of patients with moderate to severe chronic occlusive arterial disease; future controlled trials in such patients are now justified.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease

Lee

Berkowitz

Savitsky

et al. 1985

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…Evidence is split regarding the benefits of pentoxifylline in PAD with 1 randomized trial showing improved lower extremity symptoms with increased claudication distance. 31 However, a more recent study showed that this agent was no more effective than placebo in increasing maximal treadmill walking distance or improving quality of life. 32 A meta-analysis of all pentoxifylline studies concluded that the drug may have a small effect on walking ability, but the data is insufficient to support its widespread use.…”

Section: Drug Therapy For Claudicationmentioning

confidence: 99%

Peripheral Arterial Disease—What Do We Need to Know?

Shanmugasundaram

Ram

Luft

et al. 2011

Clinical Cardiology

View full text Add to dashboard Cite

Peripheral artery disease (PAD) results from progressive narrowing of arteries secondary to atherosclerosis and is defined as an Ankle Brachial Index of <0.9. PAD is highly prevalent and is an increasing burden on both the economy and the patient, especially given the rapid shift in demographics in the United States. Despite its prevalence and association with cardiovascular disease, PAD is still underdiagnosed and undertreated. This may, in part, be related to lack of recognition from the physician's side or paucity of evidence from clinical trials. It has been shown that medical therapy approved for cardiovascular disease is effective in the treatment of PAD and decreases cardiovascular events. Various revascularization strategies are also available for improving symptoms and quality of life in these patients, yet they are underutilized. In an attempt to increase its recognition, PAD has been considered a coronary artery disease equivalent. This article reviews the diagnosis and management of PAD. © 2011 Wiley Periodicals, Inc.The authors have no funding, financial relationships, or conflicts of interest to disclose.

show abstract

“…12 Pentoxifylline should be reserved for patients who cannot take cilostazol, have not responded adequately to an exercise program, and/or are not candidates for revascularization procedures or clinical trials. 117,[122][123][124][125] Cilostazol. The mechanism by which cilostazol, a phosphodiesterase type 3 inhibitor, improves claudication is unknown, but the medication has the following properties: antiplatelet activity, vasodilatory properties, and in vitro inhibition of vascular smooth muscle cells.…”

mentioning

confidence: 99%

Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management

Olin

Sealove

2010

Mayo Clinic Proceedings

268

183

View full text Add to dashboard Cite

Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

Cited by 390 publications

References 7 publications

Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease

Pentoxifylline treatment of moderate to severe chronic occlusive arterial disease

Peripheral Arterial Disease—What Do We Need to Know?

Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management

Contact Info

Product

Resources

About